Veru's enobosarm showed significant body composition benefits in Phase 2b trials with semaglutide. Extension study results ...

On Monday, Veru Inc (VERU) stock saw a decline, ending the day at $0.64 which represents a decrease of $-0.57 or -47.11% from the prior close of $1.21. The stock opened at $0.64 and touched a low of ...

It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Veru Inc. Currently has a Zacks ...

Notable insider trades include STEINER MITCHELL SHUSTER, President and CEO at Veru Inc (VERU), who sold 84021 shares on May 15 ’24, at $1.5 each, totaling $0.13 million.

Oppenheimer reiterated its Outperform rating and $5.00 price target for Veru Inc. (NASDAQ:VERU) shares, following the ...

The scale of the decline in Veru's shares despite the positive result may reflect the amplified expectations of investors for ...

InvestingPro data shows the stock has demonstrated strong resilience, often moving independently of broader market trends. The focus is on the potential of enobosarm, Veru's investigational drug ...

Veru Inc. (NASDAQ:VERU – Get Free Report) was the target of unusually large options trading on Tuesday. Stock investors acquired 8,511 call options on the stock. This represents an increase of 500% ...